Pursuant to provisions of Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental's board, meeting on August 14, 2025, approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) along with the notice and book closure for the AGM scheduled on September 30, 2025. On a standalone basis, revenue from operations rose to Rs 1,306.68 lakhs (up ~13% from Rs 1,151.99 lakhs in Q1 FY25) and profit after tax improved to Rs 55.60 lakhs (from Rs 49.71 lakhs), with EPS of Rs 0.56. However, on a consolidated basis, the company swung to a loss after tax of Rs 248.80 lakhs versus a profit of Rs 108.32 lakhs in the year-ago quarter, mainly because subsidiaries contributed a net loss of Rs 304.40 lakhs despite revenues of Rs 1,064.73 lakhs. The auditor (V. Goswami & Co) issued an unmodified (clean) review opinion on both sets of results. The group also restated prior-period consolidated figures after switching its joint venture (Medico Lab) from proportionate consolidation to the equity method under Ind AS 28.
Standalone performance is steady with modest growth, but the consolidated loss — driven by losses in subsidiaries — is a red flag for shareholders and may put short-term pressure on the stock. The clean auditor opinion and AGM-related disclosures are routine, with no dividend or capital action announced.